# Inhibrx (INBX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/INBX
## Company Profile
- Ticker: INBX
- Exchange: NASDAQ
- Sector: Biopharmaceuticals
- Location: United States
- Tags: Biopharma, Oncology
## Stock Data
- Close: 87.39 USD
- Market cap: 1364567009.8600001 USD
- Last updated: 2026-07-17
## Business Overview
Inhibrx is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
## Why The Stock Is Moving

INBX is trading like a clinical-stage oncology name where the main driver is whether the next update strengthens confidence in the pipeline. The stock usually reacts to readouts, safety, financing, and partnership signals more than to broad sector moves.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Inhibrx is followed within the biotech universe for its exposure to catalyst-driven execution.

## Business Model

Inhibrx follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.

## Landscape Position

Compared with more mature healthcare peers, Inhibrx sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.

## Future Catalysts

- The next three months should center on clinical updates, development milestones, and any commentary that clarifies the path for ozekibart or the broader biologics platform.
- Investors will also watch financing flexibility and strategic alternatives because clinical-stage oncology names tend to reprice quickly when capital structure or partner interest changes.
- Conference posters, investigator updates, and regulatory feedback can all matter if they change the market's confidence in activity or differentiation.
- For a company like Inhibrx, one clear efficacy or safety signal can move the investment case more than several smaller follow-on updates.

## Drug Assets

- INBRX-106

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 13:00 EST — [Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million](https://biopharmsignal.com/news/INBX/inhibrx-announces-amended-loan-agreement-with-oxford-finance-expanding-total-fac-d29cd85b) — Source: Inhibrx
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck